Treatment responses to @entity2213 vary among @entity1 with @entity1860 ( @entity1860 ), and definitions of treatment failure and suboptimal response have been published. This article discusses monitoring and treatment of @entity1 with @entity1860 after failure of or suboptimal response to @entity2213 therapy. We reviewed articles listed on PubMed from January 1, 2002, to July 31, 2008, and abstracts from the 2007 Annual Meeting of the American Society of Hematology. Search terms used were chronic myeloid/ @entity2800 , @entity2213 , and @entity1861 . To enable early recognition of suboptimal responses, @entity1 should be frequently monitored according to published guidelines, including cytogenetic analysis every 6 months until a complete response is achieved and molecular monitoring every 3 months from the start of therapy or monthly if an increasing BCR-ABL1 transcript level is detected. Mutational analysis of BCR-ABL1 may assist with treatment selection. A recent survey suggests that a notable proportion of physicians do not follow treatment guidelines and that broader communication is required. Recent recommendations state that, in @entity1 whose response to @entity2213 at 400 mg/d is suboptimal, the dose should be increased, whereas alternative therapies, such as @entity8947 , @entity10542 , and allogeneic stem cell transplant (in eligible @entity1 ), and @entity2213 dose escalation should be considered after @entity2213 failure. However, clinical data are lacking to confirm this sequence of treatments, and introducing alternative therapies at an earlier stage of treatment, for example, after a suboptimal response, may produce better long-term outcomes in a higher proportion of @entity1 . @entity1 and disease characteristics should be carefully considered to optimize treatment strategy for @entity1860 .

Suboptimal response to or failure of XXXX treatment for @entity1860 : what is the optimal strategy?

@entity1 :: ('9606', 'Species') :: ['patients', 'Patient'] @entity1861 :: ('25', 'Gene') :: ['BCR-ABL'] @entity8947 :: ('MESH:C488369', 'Chemical') :: ['dasatinib'] @entity2800 :: ('MESH:D007951', 'Disease') :: ['myelogenous leukemia'] @entity2213 :: ('MESH:C097613', 'Chemical') :: ['imatinib'] @entity10542 :: ('MESH:C498826', 'Chemical') :: ['nilotinib'] @entity1860 :: ('MESH:D015464', 'Disease') :: ['CML', 'chronic myeloid leukemia']
@entity2213 :: (MESH:C097613,Chemical) :: ['imatinib']
